Siwen Hu-Lieskovan

Siwen Hu-Lieskovan

UNVERIFIED PROFILE

Are you Siwen Hu-Lieskovan?   Register this Author

Register author
Siwen Hu-Lieskovan

Siwen Hu-Lieskovan

Publications by authors named "Siwen Hu-Lieskovan"

Are you Siwen Hu-Lieskovan?   Register this Author

33Publications

1019Reads

37Profile Views

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Cell Stem Cell 2019 Oct 5;25(4):542-557.e9. Epub 2019 Sep 5.

Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2019.08.004DOI Listing
October 2019

Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

Lancet Oncol 2019 Sep 25. Epub 2019 Sep 25.

Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30619-9DOI Listing
September 2019

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:147-164. Epub 2019 May 17.

5 Division of Hematology and Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_240837DOI Listing
January 2019

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.

Cancer J 2017 Jan/Feb;23(1):10-22

From the Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844278PMC
August 2017

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Cell Rep 2017 05;19(6):1189-1201

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA; Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247173052
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2017.04.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420824PMC
May 2017

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Cell 2017 02;168(4):707-723

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles and the Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.01.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391692PMC
February 2017

What does PD-L1 positive or negative mean?

J Exp Med 2016 12 30;213(13):2835-2840. Epub 2016 Nov 30.

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095.

View Article

Download full-text PDF

Source
http://www.jem.org/lookup/doi/10.1084/jem.20161462
Publisher Site
http://dx.doi.org/10.1084/jem.20161462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154949PMC
December 2016

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Cancer Immunol Res 2016 10 2;4(10):845-857. Epub 2016 Sep 2.

Division of Hematology/Oncology, Department of Medicine, University of California (UCLA), Los Angeles, California. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, California. Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050168PMC
http://dx.doi.org/10.1158/2326-6066.CIR-16-0060DOI Listing
October 2016

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

N Engl J Med 2016 Sep 13;375(9):819-29. Epub 2016 Jul 13.

From the University of California, Los Angeles (UCLA) (J.M.Z., A.G.-D., D.S.S., H.E.-O., W.H., S.H.-L., D.Y.T., G.A.-R., S.S., L.B., J.S., B.H.M., B.C., K.R., I.P.S., P.J.S., C.P.-S., G.C., E.S., X.K., J.P., B.B.-M., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.), and Jonsson Comprehensive Cancer Center (B.C., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.) - both in Los Angeles; and the Division of Immunology, Netherlands Cancer Institute, Amsterdam (R.M., T.N.M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1604958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007206PMC
September 2016

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.

Oncoimmunology 2016 Jul 17;5(7):e1052212. Epub 2015 Aug 17.

Department of Medicine; Division of Hematology/Oncology; University of California, Los Angeles (UCLA); Los Angeles, CA USA; Department of Molecular and Medical Pharmacology; University of California, Los Angeles (UCLA); Los Angeles, CA USA; The Jonsson Comprehensive Cancer Center (JCCC); University of California, Los Angeles (UCLA); Los Angeles, CA USA; Surgery; Division of Surgical Oncology; University of California, Los Angeles (UCLA); Los Angeles, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1052212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006894PMC
July 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Cell 2016 Mar 17;165(1):35-44. Epub 2016 Mar 17.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.02.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437PMC
March 2016

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Semin Immunol 2016 02 6;28(1):73-80. Epub 2016 Feb 6.

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smim.2016.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933650PMC
February 2016

Excluding T Cells: Is β-Catenin the Full Story?

Cancer Cell 2015 Jun;27(6):749-50

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Surgery, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Medical and Molecular Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center (JCCC) at UCLA, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108150019
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2015.05.014DOI Listing
June 2015

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

BMC Cancer 2015 May 5;15:356. Epub 2015 May 5.

Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1377-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432503PMC
May 2015

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Sci Transl Med 2015 Mar;7(279):279ra41

Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA. Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA. Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4691DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765379PMC
March 2015

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

J Clin Oncol 2014 Jul 23;32(21):2248-54. Epub 2014 Jun 23.

Siwen Hu-Lieskovan, Lidia Robert, Blanca Homet Moreno, and Antoni Ribas, University of California Los Angeles, Los Angeles, CA; and Blanca Homet Moreno, Carlos III Health Institute, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.1377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164812PMC
July 2014

A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results.

Bioconjug Chem 2005 Sep-Oct;16(5):1071-80

Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc0501146DOI Listing
December 2005

EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.

Cancer Res 2005 Jun;65(11):4633-44

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2857DOI Listing
June 2005